Latest Compare Stories
NEW ORLEANS, April 3, 2011 /PRNewswire/ -- A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's (NYSE: ABT) market-leading XIENCE VÂ® Everolimus Eluting Coronary Stent System.
The RAND Corporation today launched an online tool to provide policymakers and interested parties with a unique way of understanding and evaluating the effects and unintended consequences of health care reform proposals certain to be introduced in the new 111th Congress and beyond.
'COMPARE' provides global positioning system for health care policy WASHINGTON, Jan.
- a meat pie that is usually eaten at Christmas in Quebec